Why Revelation Biosciences (REVB) Stock Is Down 38%
Why Revelation Biosciences (REVB) Stock Is Down 38%
Revelation Biosciences Inc (NASDAQ:REVB) shares are trading lower by 38% to 58 cents during Tuesday's session after the company said it entered a definitive agreement for the immediate exercise of outstanding warrants to purchase 4,064,040 shares of common stock at $1.00 per share.
启示生物科学公司（纳斯达克：REVB）在周二的交易中股价下跌38%，至58美分，此前该公司表示已达成一项关于立即行使未行使warrants的正式协议，以购买4,064,040股普通股，价格为每股1.00美元。
The shares, registered under a Form S-3 filing, are expected to generate approximately $4 million in proceeds. The transaction is set to close on December 3, pending customary conditions.
这些股份在S-3表格备案中注册，预计将产生约400万美元的收益。此次交易预计将在12月3日完成，待符合惯例条件。
Roth Capital Partners is serving as the financial advisor for the deal. REVB shares otherwise gained Monday after the company announced FDA acceptance of Gemini IND.
罗斯资本伙伴公司担任该交易的财务顾问。除此外，REVb股票在周一上涨，此前该公司宣布FDA接受了Gemini IND。
Read Also: South Korean ETFs Slide On President's Emergency Martial Law Declaration: 'Protect The Constitutional Democratic Order'
另请阅读：韩国etf在总统实施紧急戒严令时下滑：'保护宪法民主秩序'
According to data from Benzinga Pro, REVB has a 52-week high of $25.26 and a 52-week low of $0.51.
根据Benzinga Pro的数据，REVb的52周高点为25.26美元，52周低点为0.51美元。
